<code id='971C47F4CC'></code><style id='971C47F4CC'></style>
    • <acronym id='971C47F4CC'></acronym>
      <center id='971C47F4CC'><center id='971C47F4CC'><tfoot id='971C47F4CC'></tfoot></center><abbr id='971C47F4CC'><dir id='971C47F4CC'><tfoot id='971C47F4CC'></tfoot><noframes id='971C47F4CC'>

    • <optgroup id='971C47F4CC'><strike id='971C47F4CC'><sup id='971C47F4CC'></sup></strike><code id='971C47F4CC'></code></optgroup>
        1. <b id='971C47F4CC'><label id='971C47F4CC'><select id='971C47F4CC'><dt id='971C47F4CC'><span id='971C47F4CC'></span></dt></select></label></b><u id='971C47F4CC'></u>
          <i id='971C47F4CC'><strike id='971C47F4CC'><tt id='971C47F4CC'><pre id='971C47F4CC'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:comprehensive    Page View:59257
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In